Literature DB >> 7015512

Prostacyclin: a potent antimetastatic agent.

K V Honn, B Cicone, A Skoff.   

Abstract

Metastasis is the principal cause of failures to cure human cancers. Prostacyclin is a powerful antimetastatic agent against B16 amelanotic melanoma cells. This effect, which may result from the platelet antiaggregatory action of prostacyclin, is potentiated by a phosphodiesterase inhibitor. Inhibitors of prostacyclin synthesis increase metastasis. Prostacyclin and agents that may increase endogenous prostacyclin production or prolong its activity are suggested as new antimetastatic agents.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7015512     DOI： 10.1126/science.7015512

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  82 in total

1.  Oral iloprost improves endobronchial dysplasia in former smokers.

Authors:  Robert L Keith; Patrick J Blatchford; John Kittelson; John D Minna; Karen Kelly; Pierre P Massion; Wilbur A Franklin; Jenny Mao; David O Wilson; Daniel T Merrick; Fred R Hirsch; Timothy C Kennedy; Paul A Bunn; Mark W Geraci; York E Miller
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

Review 2.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 3.  Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract.

Authors:  S Nigam; A Zakrzewicz; S Eskafi; A Roscher
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

4.  Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer.

Authors:  I Klapan; V Katić; F Culo; V Cuk
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.

Authors:  Howard Y Li; Maria McSharry; Deandra Walker; Amber Johnson; Jeff Kwak; Bonnie Bullock; Alexander Neuwelt; Joanna M Poczobutt; Trisha R Sippel; Robert L Keith; Mary C M Weiser-Evans; Eric Clambey; Raphael A Nemenoff
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

Review 6.  Role of plasma, platelets, and endothelial cells in tumor metastasis.

Authors:  G J Gasic
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

7.  Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase.

Authors:  J Yahalom; A Eldor; Z Fuks; I Vlodavsky
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

8.  Interleukin 1-induced cancer cell/endothelial cell adhesion in vitro and its relationship to metastasis in vivo: role of vessel wall 13-HODE synthesis and integrin expression.

Authors:  M C Bertomeu; S Gallo; D Lauri; T A Haas; F W Orr; E Bastida; M R Buchanan
Journal:  Clin Exp Metastasis       Date:  1993-05       Impact factor: 5.150

9.  Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.

Authors:  C D Haas; G W Kyle; J D Crissman; M F Schaldenbrand
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

10.  Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Authors:  F Formelli; L Cleris; R Carsana
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.